NBMI - Clinical Study on COPD

Summary

A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate and severe COPD with bronchitis A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days pilot study in subjects with COPD with bronchitis.

Timeline

Start

2017-01-01

Primary completion

2018-05-30

Completion

2018-06-30

Drugs

Indications